secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001558370-24-007692
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix Q1 net loss $4.6M; PRX-115 phase I positive, adds cohort
-----------------------------------------------------------------

- Revenue from goods $3.7M (-27% YoY); license/R&D services $0.1M (-98%) as Elfabrio obligations completed.
- Net loss $4.6M ($0.06/shr) vs $3.1M loss ($0.05) YoY; cash $48.5M at quarter end.
- PRX-115 phase I: dose-dependent uric acid reduction, well-tolerated; expanding to 8th cohort, planning phase II.
- R&D expenses down 50% to $2.9M on completion of Fabry program and Elfabrio regulatory filings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837024007692/0001558370-24-007692-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837024007692/plx-20240510x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007692

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer